Guodong Liu1, Nicholas W Sterling2, Lan Kong1, Mechelle M Lewis2,3, Richard B Mailman2,3, Honglei Chen4, Douglas Leslie1, Xuemei Huang2,3. 1. Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA. 2. Department of Neurology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA. 3. Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA. 4. Department of Epidemiology, Michigan State University, East Lansing, Michigan, USA.
Abstract
OBJECTIVE: Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson's disease (PD). METHODS: We performed a retrospective case-control analysis. First, we identified 2322 incident PD cases having a minimum of 2.5 years of continuous enrollment prior to earliest diagnosis code or prescription of antiparkinson medication. A total of 2322 controls were then matched individually by age, gender, and a follow-up window to explore the relationship of statin use with incident PD. RESULTS: Statin usage was significantly associated with PD risk, with the strongest associations being for lipophilic (odds ratio = 1.58, P < .0001) versus hydrophilic (odds ratio = 1.19, P = .25) statins, statins plus nonstatins (odds ratio = 1.95, P < .0001), and for the initial period after starting statins (<1 year odds ratio = 1.82, 1-2.5 years odds ratio = 1.75, and ≥2.5 years odds ratio = 1.37; Ptrend < .0001). CONCLUSION: The use of statin (especially lipophilics) was associated with higher risk of PD, and the stronger association in initial use suggests a facilitating effect.
OBJECTIVE: Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson's disease (PD). METHODS: We performed a retrospective case-control analysis. First, we identified 2322 incident PD cases having a minimum of 2.5 years of continuous enrollment prior to earliest diagnosis code or prescription of antiparkinson medication. A total of 2322 controls were then matched individually by age, gender, and a follow-up window to explore the relationship of statin use with incident PD. RESULTS: Statin usage was significantly associated with PD risk, with the strongest associations being for lipophilic (odds ratio = 1.58, P < .0001) versus hydrophilic (odds ratio = 1.19, P = .25) statins, statins plus nonstatins (odds ratio = 1.95, P < .0001), and for the initial period after starting statins (<1 year odds ratio = 1.82, 1-2.5 years odds ratio = 1.75, and ≥2.5 years odds ratio = 1.37; Ptrend < .0001). CONCLUSION: The use of statin (especially lipophilics) was associated with higher risk of PD, and the stronger association in initial use suggests a facilitating effect.
Authors: Benjamin L Deck; Jacqueline Rick; Sharon X Xie; Alice Chen-Plotkin; John E Duda; James F Morley; Lana M Chahine; Nabila Dahodwala; John Q Trojanowski; Daniel Weintraub Journal: J Parkinsons Dis Date: 2017 Impact factor: 5.568
Authors: Michał Kosowski; Joanna Smolarczyk-Kosowska; Marcin Hachuła; Mateusz Maligłówka; Marcin Basiak; Grzegorz Machnik; Robert Pudlo; Bogusław Okopień Journal: Molecules Date: 2021-05-11 Impact factor: 4.411
Authors: Lijun Zhang; Xue Wang; Ming Wang; Nick W Sterling; Guangwei Du; Mechelle M Lewis; Tao Yao; Richard B Mailman; Runze Li; Xuemei Huang Journal: Front Neurol Date: 2017-09-27 Impact factor: 4.003